Evaluation of the Efficacy of Two Dietary Supplements on Hair Loss and Hair Aspect
NCT ID: NCT06028295
Last Updated: 2024-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
99 participants
INTERVENTIONAL
2023-09-04
2023-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
NCT05954039
The Effect of 24-week Dietary Intake of Food Supplements on Hair
NCT06174441
Study to Evaluate a Nutraceutical Supplement for Treatment of Hair Loss and Thinning in Females
NCT03052413
Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men
NCT06362941
Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
NCT03709563
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wheat Polar Lipid Complex Oil
Dietary supplement - Wheat Polar Lipid Complex (Oil)
Wheat Polar Lipid Complex Oil
The study foresees the intake of 2 capsules per day during 84 days
Wheat Polar Lipid Complex Powder
Dietary supplement - Wheat Polar Lipid Complex (Powder)
Wheat Polar Lipid Complex Powder
The study foresees the intake of 2 capsules per day during 84 days
Placebo
Dietary supplement - Placebo
Placebo
The study foresees the intake of 2 capsules per day during 84 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Wheat Polar Lipid Complex Oil
The study foresees the intake of 2 capsules per day during 84 days
Wheat Polar Lipid Complex Powder
The study foresees the intake of 2 capsules per day during 84 days
Placebo
The study foresees the intake of 2 capsules per day during 84 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Caucasian ethnicity,
* Age between 18 and 65 years old (extremes included),
* All hair type included,
* Subject showing acute hair shedding (duration less than 6 months) due to fatigue, seasonal change, deficiency of vitamins and minerals, stress, change or imbalance of normal daily routing, or emotional stress,
* Women showing a proportion of hair in telogen phase \> 15%,
* Subjects complaining brittle and thin hair,
* Subjects who stopped any anti hair loss treatment at least 3 months prior the study,
* Subjects agreeing not to take any treatment (oral or topic) able to interfere with the hair growth, diameter or fall during the whole study duration,
* Subjects who have not been involved in any other similar study in the last 3 months,
* Subjects registered with health social security or health social insurance, Subjects able to understand the language used in the investigation center and the information given
* Subjects able to comply with the protocol and follow protocol's constraints and specific requirements
* Willingness to use the same products for hair care during all the study period
* Willingness not to cut hair for all the study length.
* Subjects having signed their written Informed Consent form (ICF) for their participation in the study and a photograph authorization.
* Subject is taking part or planning to participate to another clinical study in the same or in another investigation centre,
* Subject is deprived of freedom by administrative or legal decision or under guardianship,
* Subject is admitted in a sanitary or social facilities,
* Subject is planning an hospitalization during the study,
* Subject has participated in another clinical study with anti-hair loss product or treatment within the last 3 months before the inclusion visit,
* Subject is breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential),
* Subject has started or changed oestrogen-progesterone contraception or hormonal treatment, within the 3 months prior to the study or foreseeing it for the duration of the study,
* Subject having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements,
* Subject is in course of a long-treatment or intending to have one considered by the Investigator liable to interfere with the study data or incompatible with the study requirements,
* Subject having a skin/scalp condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements,
* Subject having personal history of cosmetic, drug, domestic products or food supplements allergy,
* Subject having food disorders,
* Subject who has any other hair disorder or hair disease (female pattern hair loss, any type of alopecia...),
* Subject having excessive and/or fluctuating hair shedding for more than 6 months,
* History or clinical signs of hyperandrogenemia (menstrual cycle \>35 days and hirsutism and acne),
* Systemic treatment affecting the hair growth taken for more than 4 consecutive weeks during the last 24 weeks before inclusion visit: retinoids, anti-mitotic, cytotoxic drugs other than antineoplastic, anti-androgens (spironolactone, flutamide), androgens, anti-epileptic agents, interferon alpha,
* Systemic or local androgenetic alopecia treatment or product, taken or applied (Minoxidil, Aminexil, Finasteride, Dutasteride, cosmetic solution or capsules with vitamin B, zinc, caffeine...) for more than 4 consecutive weeks during the last 24 weeks before the inclusion visit,
* Any other topical treatment applied on the scalp (non-steroidal anti-inflammatory, ketoconazole...) within the last 2 weeks before the inclusion visit,
* No hair wash in the 48 hours before each visit,
* Any following hair care within the last 2 weeks before each visit: dandruff shampoo, antifungal shampoo, dyeing, bleaching, perm,
* Any hair care product applied on the scalp between the last shampoo and the inclusion visit (e.g. gel, hairspray, wax, foam...),
* Radiotherapy, chemotherapy at any time,
* Scalp surgery (hair transplants, laser) at any time.
18 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seppic
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ileana De Ponti
Role: STUDY_DIRECTOR
Complife Italia S.r.l
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complife Italia srl
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IT0003622/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.